CRISPR Therapeutics AG
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $3.5M | $37.3M | $371.2M | $1.2M | $915.0M |
| Operating income | -$664.6M | -$466.6M | -$222.5M | -$673.2M | $373.5M |
| Operating expenses | $668.1M | $503.9M | $593.7M | $674.4M | $541.4M |
| Cash from operations | -$345.0M | -$142.8M | -$260.4M | -$495.7M | $539.0M |
| Capital expenditure | $914,000 | $1.9M | $9.5M | $37.2M | $81.7M |
| Free cash flow | -$345.9M | -$144.7M | -$269.8M | -$532.9M | $457.3M |
| Total assets | $2.3B | $2.2B | $2.2B | $2.2B | $2.8B |
| Total liabilities | $343.4M | $310.0M | $346.8M | $367.6M | $352.4M |
Shares outstanding 96.4M · Free float 81.6%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.